Insulin Patch Pumps Market Size, Share | Report 2022-2030
The global insulin patch pumps market was estimated at USD 836.22 million in 2021 and it is expected to surpass around USD 2.3 billion by 2030, poised to grow at a CAGR of 11.9% from 2022 to 2030.
Report Highlights
The market is primarily driven by factors such as increasing diabetic population and rising awareness regarding advanced diabetes management solutions. Moreover, technological advancements and several product launches in the field of insulin patch pumps are further augmenting the growth.
Patch pumps are easy to use and more convenient than conventional insulin pumps. Usually, these pumps are connected to a continuous or blood glucose monitoring system. In addition, patch pumps are more affordable than conventional insulin pumps and are rapidly capturing a significant share in the insulin delivery market. Key market players are using novel technologies and offering user-friendly insulin delivery solutions at lower prices. This is expected to increase the frequency of product launches during the forecast period, thus boosting the overall industry growth.
Increasing healthcare expenditure related to diabetes and the rising number of FDA approvals are further aiding the industry growth. According to the International Diabetes Federation, the global total diabetes-related health expenditure was about USD 966,000 Million, which is expected to increase to USD 1,053,700 Million by 2045. In March 2019, EoFlow, a South Korean Company, received FDA approval for its newly designed patch pump, EoPatch in the U.S. Moreover, the growing geriatric population is expected to aid the market growth over the forecast period. According to the "Aging in the United States" report by the Population Reference Bureau, there will be more than 98 million people in the U.S. who are 65 years of age or older by 2060, up from about 46 million in 2016.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 836.22 million |
| Revenue Forecast by 2030 | USD 2.3 billion |
| Growth rate from 2022 to 2030 | CAGR of 11.9% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Delivery mode, product type, distribution channel, region |
| Companies Covered | Medtronic plc; F. Hoffmann-La Roche Ltd.; Insulet Corporation; CeQur; Terumo; Tandem Diabetes Care; Medtrum; Debiotech |
Delivery Mode Insights
The basal and bolus segment dominated the market in 2021 with a revenue share of over 55.04% and is expected to maintain its position over the forecast period owing to the advanced features and the availability of a wide variety of products. Basal and bolus therapy helps normalize blood sugar levels without increasing the risk of hypoglycemia. Moreover, basal and bolus therapy includes an injection after each meal, which emulates the activity of the healthy pancreas. In addition, these therapies are used by both type 1 and type 2 diabetes patients, hence dominating the market. Based on the delivery mode, the market is segmented into basal, bolus, and basal and bolus.
The basal segment captured a significant share in 2021 and is anticipated to grow at a rapid pace. This high growth rate can primarily be attributed to increased adoption among type 1 diabetes patients. Basal insulin pump therapy acts on a slow release mechanism, which is important for managing type 1 diabetes. All types of basal insulins are long-acting and mimic the natural function of the pancreas.
Product Type Insights
The reusable insulin patch pump segment dominated the market in 2021 with a revenue share of over 60.3% and is expected to maintain its dominance over the forecast period. This can be attributed to the increased adoption of these pumps and high frequency of product launches. These devices are highly flexible and capable of delivering complex regimens of insulin to patients. Based on product type, the market is segmented into disposable and reusable patch pumps.
Disposable insulin pumps are mechanical pumps and are also called simplified devices. The majority of these types of patch pumps have some disposable parts, while others are completely disposable. Currently, V-Go by Valeritas and PAQ by CeQur dominate the market as they have a strong presence in the U.S. as well as Europe. Such patch pumps provide consistent and adjustable insulin delivery, with fewer insulin injections.
Distribution Channel Insights
The hospitals segment dominated the market in 2021 with a revenue share of over 50.4% owing to factors such as increasing number of specialty hospital pharmacies and the expansion of the integrated delivery network. Most first-time patch pump users tend to buy these from hospital pharmacies. Considering the recent shift in trend from traditional to automated insulin delivery solutions, the hospital pharmacy segment is expected to witness significant growth over the forecast period. By distribution channel, the market is segmented into hospitals, retail pharmacies, private clinics, online pharmacies, and others.
The online pharmacies segment is expected to exhibit the fastest CAGR during the forecast period. The high growth rate of the segment can primarily be attributed to factors such as rising awareness regarding online pharmacies, lower costs, convenience, and increase in awareness campaigns by online pharmacies. However, purchasing insulin patches through online pharmacies may involve risks such as wrong product delivery and improper usage.
Regional Insights
North America dominated the market with a revenue share of over 35.11% in 2021 owing to the availability of major brands of insulin patch pumps. Moreover, increasing healthcare expenditure and rising frequency of FDA approvals are aiding market growth in the region. For instance, in 2019, EoFlow, a South Korean Company, received FDA approval for its newly designed patch pump-EOPatch-in the U.S. Moreover, according to the International Diabetes Federation, the diabetic-related healthcare expenditure per person in the U.S. was about USD 8,468 in 2011, which increased to USD 11,779 in 2021, and is further expected to increase to USD 12,184 by 2045.
Asia Pacific is expected to grow at the fastest rate over the forecast period due to factors such as the rapidly growing diabetic population and increasing awareness regarding advanced diabetes management solutions in the region. According to the International Diabetes Federation, India and China account for the largest number of diabetes patients in the world. Most of the countries in this region are developing countries and the increase in obesity cases and growing socio-economic changes have fueled the occurrence of type I and type II diabetes. In addition, increasing product launches and technological advancements in the field of insulin patch pumps are expected to aid regional growth.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Insulin Patch Pumps Market
5.1. COVID-19 Landscape: Insulin Patch Pumps Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Insulin Patch Pumps Market, By Delivery Mode
8.1. Insulin Patch Pumps Market, by Delivery Mode, 2022-2030
8.1.1 Basal
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Bolus
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Basal & Bolus
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Insulin Patch Pumps Market, By Product Type
9.1. Insulin Patch Pumps Market, by Product Type, 2022-2030
9.1.1. Disposable
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Reusable
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Insulin Patch Pumps Market, By Distribution Channel
10.1. Insulin Patch Pumps Market, by Distribution Channel, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Private Clinics
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Online Pharmacies
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Insulin Patch Pumps Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.1.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.2.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.3.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.4.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.5.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Product Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 12. Company Profiles
12.1. Medtronic plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. F. Hoffmann-La Roche Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Insulet Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. CeQur
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Terumo
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Tandem Diabetes Care
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Medtrum
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Debiotech
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers